Daily Medication Pearl: Natalizumab (Tysarbi)


Natalizumab (Tysarbi) is an integrin receptor antagonist indicated for treatment of: multiple sclerosis and Crohn disease.

Medication Pearl of the Day: Natalizumab (Tysarbi)

Indication: Natalizumab (Tysarbi) is an integrin receptor antagonist indicated for treatment of multiple sclerosis (MS) and Crohn disease.


  • Dosing: 300 mg infused intravenously over 1 hour, every 4 weeks. Do not give as an intravenous push or bolus.
  • Dosage forms: Injection 300 mg/15 mL (20 mg/mL) solution in a single-dose vial for dilution prior to infusion.
  • Adverse events: Most common adverse reactions (incidence ³ 10%) with natalizumab in MS are headache, fatigue, arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea NOS, and rash.
  • Mechanism of action: Natalizumab binds to the a4-subunit of a4b1 and a4b7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the a4-mediated adhesion of leukocytes to their counter-receptor(s)


tysabri_prescribing_information.pdf (tysabrihcp.com)

Related Videos
Image credit:  Chanintorn.v | stock.adobe.com - PTSD Mental health concept, Psychologist sitting and touch hand young depressed asian man for encouragement near window with low light environment.Selective focus.
Image credit: сергей костюченко | stock.adobe.com - human head with brain
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.